Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Buserelin |
Synonyms | |
Therapy Description |
Buserelin is a gonadotropin-releasing hormone (GnRH) analog that activates pituitary GnRH receptors, potentially resulting in reduced synthesis of gonadotropin and decreased levels of circulating gonadotropin and gonadal steroids (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Buserelin | Buserelin acetate|HOE 766|ICI 123215|S74-6766 | Buserelin is a gonadotropin-releasing hormone (GnRH) analog that activates pituitary GnRH receptors, potentially resulting in reduced synthesis of gonadotropin and decreased levels of circulating gonadotropin and gonadal steroids (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05050084 | Phase III | Buserelin Relugolix Degarelix Goserelin Leuprolide Histrelin acetate Triptorelin Darolutamide + Goserelin Bicalutamide Darolutamide + Degarelix Darolutamide + Leuprolide Darolutamide + Triptorelin Buserelin + Darolutamide Darolutamide + Histrelin acetate Flutamide Darolutamide + Relugolix | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | Recruiting | USA | CAN | 0 |